Trial Profile
A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results assessing combined expression of MKI67, FOXC1 and PDL1 is a pan-tumor tissue-agnostic predictor of PD1/PDL1 inhibitor efficacy presented at the 48th European Society for Medical Oncology Congress
- 24 Feb 2022 Status changed from active, no longer recruiting to completed.
- 26 Aug 2020 Planned End Date changed from 8 Jun 2020 to 30 Nov 2020.